Previous 10 | Next 10 |
home / stock / bbio / bbio articles
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" ...
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday. Shares of ResMed Inc. (NYSE:RMD) fell sharply during Monday...
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage bio...
Tuesday, BridgeBio Pharma Inc (NASDAQ:BBIO) announced sustained results from the PROPEL 2 Phase 2 trial of the investigational therapy infigratinib...
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is moving lower Tuesday after the company announced results from its Phase 2 trial of infigratinib in childre...
PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (BridgeBio), a commercial-stage biopharmaceutical comp...
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biop...
PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage biopharmaceutical c...
Monday, BridgeBio Pharma Inc (NASDAQ:BBIO) and Bayer AG (OTC:BAYRY) (OTC:BAYZF) announced a partnership wherein BridgeBio grant...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO...